Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response.

Autor: Lee, Quintin, Song, Renhua, Phan, Dang Anh Vu, Pinello, Natalia, Tieng, Jessica, Su, Anni, Halstead, James M., Wong, Alex C. H., van Geldermalsen, Michelle, Lee, Bob S.-L., Rong, Bowen, Cook, Kristina M., Larance, Mark, Liu, Renjing, Lan, Fei, Tiffen, Jessamy C., Wong, Justin J.-L.
Zdroj: Cellular & Molecular Life Sciences; Jun2023, Vol. 80 Issue 6, p1-20, 20p
Abstrakt: Virilizer-like m6A methyltransferase-associated protein (VIRMA) maintains the stability of the m6A writer complex. Although VIRMA is critical for RNA m6A deposition, the impact of aberrant VIRMA expression in human diseases remains unclear. We show that VIRMA is amplified and overexpressed in 15–20% of breast cancers. Of the two known VIRMA isoforms, the nuclear-enriched full-length but not the cytoplasmic-localised N-terminal VIRMA promotes m6A-dependent breast tumourigenesis in vitro and in vivo. Mechanistically, we reveal that VIRMA overexpression upregulates the m6A-modified long non-coding RNA, NEAT1, which contributes to breast cancer cell growth. We also show that VIRMA overexpression enriches m6A on transcripts that regulate the unfolded protein response (UPR) pathway but does not promote their translation to activate the UPR under optimal growth conditions. Under stressful conditions that are often present in tumour microenvironments, VIRMA-overexpressing cells display enhanced UPR and increased susceptibility to death. Our study identifies oncogenic VIRMA overexpression as a vulnerability that may be exploited for cancer therapy. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: